TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neurosense Therapeutics Ltd. ( (NRSN) ) just unveiled an update.
NeuroSense Therapeutics Ltd. announced the completion of data collection for its Phase 2 clinical trial of PrimeC in Alzheimer’s disease, known as the RoAD study, on December 8, 2025. The database lock signifies the trial’s readiness for final statistical analysis, with results anticipated in early 2026. This milestone could potentially enhance NeuroSense’s position in the neurodegenerative treatment market, offering insights into the efficacy of PrimeC and impacting stakeholders’ expectations.
The most recent analyst rating on (NRSN) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on developing treatments for neurodegenerative diseases. The company’s primary product is PrimeC, which is being tested for its efficacy in treating conditions such as Alzheimer’s disease.
Average Trading Volume: 619,413
Technical Sentiment Signal: Strong Sell
Current Market Cap: $34.57M
Find detailed analytics on NRSN stock on TipRanks’ Stock Analysis page.